Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Midazolam | 1 | 2017 | 8 | 0.550 |
Why?
|
| Catatonia | 1 | 2017 | 4 | 0.550 |
Why?
|
| Hypnotics and Sedatives | 1 | 2017 | 29 | 0.540 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2017 | 41 | 0.530 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2011 | 7 | 0.370 |
Why?
|
| Osteochondrodysplasias | 3 | 2016 | 3 | 0.360 |
Why?
|
| Nephrotic Syndrome | 3 | 2016 | 8 | 0.360 |
Why?
|
| Immunologic Deficiency Syndromes | 3 | 2016 | 6 | 0.360 |
Why?
|
| Arteriosclerosis | 3 | 2016 | 29 | 0.350 |
Why?
|
| Critical Care | 1 | 2011 | 49 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 243 | 0.320 |
Why?
|
| Pulmonary Embolism | 3 | 2016 | 126 | 0.320 |
Why?
|
| Postoperative Care | 2 | 2020 | 68 | 0.300 |
Why?
|
| Child | 6 | 2020 | 2242 | 0.230 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 102 | 0.230 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2020 | 3 | 0.170 |
Why?
|
| Child, Preschool | 5 | 2020 | 1146 | 0.170 |
Why?
|
| Warfarin | 1 | 2020 | 94 | 0.160 |
Why?
|
| Nitric Oxide Synthase Type III | 4 | 2007 | 55 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 224 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 173 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2020 | 294 | 0.140 |
Why?
|
| Lorazepam | 1 | 2017 | 7 | 0.140 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2017 | 22 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 607 | 0.130 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2016 | 2 | 0.130 |
Why?
|
| RNA, Messenger | 3 | 2015 | 659 | 0.130 |
Why?
|
| Wnt Proteins | 1 | 2016 | 34 | 0.130 |
Why?
|
| Receptors, Notch | 1 | 2016 | 45 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2016 | 61 | 0.130 |
Why?
|
| C-Reactive Protein | 2 | 2007 | 92 | 0.130 |
Why?
|
| RNA Precursors | 1 | 2015 | 9 | 0.120 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2015 | 20 | 0.120 |
Why?
|
| Elastin | 1 | 2015 | 22 | 0.120 |
Why?
|
| Aorta | 1 | 2015 | 124 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2020 | 2379 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 403 | 0.110 |
Why?
|
| Male | 8 | 2020 | 13491 | 0.110 |
Why?
|
| Endothelial Cells | 2 | 2007 | 352 | 0.100 |
Why?
|
| Infant | 2 | 2020 | 1004 | 0.100 |
Why?
|
| Time Factors | 1 | 2017 | 1592 | 0.100 |
Why?
|
| Emphysema | 1 | 2012 | 3 | 0.100 |
Why?
|
| Humans | 10 | 2020 | 28097 | 0.100 |
Why?
|
| Risk Factors | 1 | 2017 | 2081 | 0.090 |
Why?
|
| United Kingdom | 1 | 2011 | 76 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2011 | 885 | 0.090 |
Why?
|
| Critical Illness | 1 | 2011 | 66 | 0.090 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2009 | 9 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 27 | 0.080 |
Why?
|
| Cells, Cultured | 5 | 2015 | 985 | 0.080 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 113 | 0.070 |
Why?
|
| Hydroxycholesterols | 1 | 2007 | 7 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2007 | 8 | 0.070 |
Why?
|
| Cardiotonic Agents | 1 | 2007 | 28 | 0.070 |
Why?
|
| Estrogens | 1 | 2007 | 56 | 0.070 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2005 | 5 | 0.060 |
Why?
|
| Lipoproteins, HDL | 1 | 2005 | 41 | 0.060 |
Why?
|
| Receptors, IgG | 1 | 2005 | 47 | 0.060 |
Why?
|
| United States | 1 | 2011 | 2146 | 0.060 |
Why?
|
| DNA Helicases | 2 | 2016 | 52 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2015 | 199 | 0.050 |
Why?
|
| Adolescent | 2 | 2020 | 3122 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2020 | 27 | 0.040 |
Why?
|
| Cattle | 3 | 2007 | 388 | 0.040 |
Why?
|
| Female | 5 | 2020 | 15156 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 343 | 0.040 |
Why?
|
| Fontan Procedure | 1 | 2020 | 24 | 0.040 |
Why?
|
| Animals | 5 | 2016 | 10423 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 1013 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2007 | 1576 | 0.030 |
Why?
|
| Mice | 4 | 2007 | 4654 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2016 | 50 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2016 | 62 | 0.030 |
Why?
|
| Nitric Oxide | 2 | 2007 | 152 | 0.030 |
Why?
|
| Gestational Age | 1 | 2015 | 146 | 0.030 |
Why?
|
| Cell Movement | 2 | 2007 | 373 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 152 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2020 | 2546 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 722 | 0.030 |
Why?
|
| Autopsy | 1 | 2012 | 25 | 0.030 |
Why?
|
| Adult | 2 | 2015 | 7740 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 520 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2015 | 301 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 463 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2007 | 6 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2007 | 33 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 34 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2007 | 62 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 60 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 78 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 40 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2007 | 43 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2007 | 55 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2007 | 54 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 116 | 0.020 |
Why?
|
| Vasodilation | 1 | 2007 | 114 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 233 | 0.020 |
Why?
|
| Kinetics | 1 | 2007 | 545 | 0.020 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2005 | 12 | 0.020 |
Why?
|
| U937 Cells | 1 | 2005 | 8 | 0.020 |
Why?
|
| Serum Amyloid P-Component | 1 | 2005 | 9 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2005 | 38 | 0.020 |
Why?
|
| Kidney | 1 | 2007 | 286 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2005 | 39 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2005 | 73 | 0.020 |
Why?
|
| Cell Line | 1 | 2007 | 696 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2005 | 71 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 507 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2007 | 848 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 578 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 7138 | 0.010 |
Why?
|